ACROMEGALY STUDY CSOM230C2305
The purpose of this clinical research study is to determine the most safe and effective dose of an investigational drug for participants who are at least 18 years old and have active acromegaly. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Participants will be asked to visit the study center 18 times over 12 months to receive treatment once a month.
Protocol Number: CSOM230C2305
If interested, contact: Ann V. Munson, MS RD, Study Coordinator
Phone: 410.502-0033
E-mail: amunson1@jhmi.edu
Or
Roberto Salvatori, MD, Principal Investigator
Phone: 410.955-3921
E-mail: salvator@jhmi.edu
Listen as
